1. Effect of Orlistat on Fecal Fat, Fecal Biliary Acids, and Colonic Cell Proliferation in Obese Subjects 
Dennis J. Ahnen, Roberto Guerciolini, Jonathan Hauptman, Steven Blotner, Cindy J. Woods, Michael J. Wargovich 
Clinical Gastroenterology and Hepatology 
Volume 5, Issue 11, Pages (November 2007)
DOI: /j.cgh
Copyright © 2007 AGA Institute Terms and Conditions

2. Figure 1
Total crypt scores (mean ± SD) defined as labeling index for BrdU and PCNA and as mitoses per crypt for WCMC at baseline and after 6 weeks of treatment with placebo or orlistat 120 mg 3 times daily.
Clinical Gastroenterology and Hepatology 2007 5, DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions

3. Figure 2
Mean change from baseline in (A) BrdU, (B) PCNA, and (C) WCMC compartmental scores after 6 weeks of treatment with placebo (○) or orlistat (■) 120 mg 3 times daily.
Clinical Gastroenterology and Hepatology 2007 5, DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions